To advance BNCT development in deep-seated cancer indications, Stella Pharma Corporation has executed an investigator-initiated clinical study agreement with Fujita Health University and others. The study will explore 18F-FBPA uptake to obtain foundational data for potential future label expansion. Based on the status as of August 2026, the impact on the fiscal year ending March 2027 is expected to be minimal.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4888","jir_company_name":"Stella Pharma Corporation","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4888-20261001-01.pdf","jir_short_summary":"To advance BNCT development in deep-seated cancer indications, Stella Pharma Corporation has executed an investigator-initiated clinical study agreement with Fujita Health University and others. The study will explore 18F-FBPA uptake to obtain foundational data for potential future label expansion. Based on the status as of August 2026, the impact on the fiscal year ending March 2027 is expected to be minimal.","jir_summary":"### Overview of Business and Research Collaboration\nStella Pharma Corporation is advancing R&D aimed at BNCT expansion into deep-seated cancer indications in collaboration with Fujita Health University, Atransen Technologies, Sumitomo Heavy Industries, and Micron. This study, announced as the execution of an investigator-initiated clinical study agreement, is an exploratory evaluation of 18F-FBPA uptake. As part of initiatives following a related memorandum of understanding dated 1994, the study will use 18F-FBPA PET to examine tumor accumulation characteristics of boron agents for BNCT.\n\n### Outlook and Impact\nThe agreement aims to accumulate foundational data for expansion into deep-seated cancer indications and may enable future BNCT label expansion. At this time, any direct impact on fiscal year 2027 performance is expected to be minimal, and the company intends to promote expansion into deep-seated cancer indications through the research collaboration.","jir_financial_highlights":"Impact on fiscal year ending March 2027: Unknown (Unknown)","jir_category":"","jir_hashtags":"#BNCT, #18F-FBPA, #ClinicalStudy, #FujitaHealthUniversity, #ResearchCollaboration","jir_key_figures":"Key figure 1: Unknown (impact on fiscal year ending March 2027 described as minimal)\nKey figure 2: Unknown (no specific contract amount or term disclosed)\nKey figure 3: Unknown (no disclosure of sales or profit items)","jir_meta_title":"Stella Pharma Corporation Executes Agreement for BNCT Research in Deep-Seated Cancers | October 2026","jir_meta_description":"Stella Pharma Corporation has executed an investigator-initiated clinical study agreement with Fujita Health University and partners to explore 18F-FBPA uptake for BNCT expansion into deep-seated cancers, aiming to accumulate foundational data. Impact on fiscal 2027 is expected to be minimal.","jir_og_title":"Stella Pharma Corporation Signs Research Agreement to Advance BNCT","jir_og_description":"An investigator-initiated clinical study to explore 18F-FBPA uptake has been agreed to support BNCT expansion into deep-seated cancer indications. Expected impact on performance is minimal.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59263,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-125669","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n